These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37547294)

  • 1. DNM2 levels normalization improves muscle phenotypes of a novel mouse model for moderate centronuclear myopathy.
    de Carvalho Neves J; Moschovaki-Filippidou F; Böhm J; Laporte J
    Mol Ther Nucleic Acids; 2023 Sep; 33():321-334. PubMed ID: 37547294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different in vivo impacts of dynamin 2 mutations implicated in Charcot-Marie-Tooth neuropathy or centronuclear myopathy.
    Massana Muñoz X; Buono S; Koebel P; Laporte J; Cowling BS
    Hum Mol Genet; 2019 Dec; 28(24):4067-4077. PubMed ID: 31628461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reducing dynamin 2 (DNM2) rescues
    Buono S; Ross JA; Tasfaout H; Levy Y; Kretz C; Tayefeh L; Matson J; Guo S; Kessler P; Monia BP; Bitoun M; Ochala J; Laporte J; Cowling BS
    Proc Natl Acad Sci U S A; 2018 Oct; 115(43):11066-11071. PubMed ID: 30291191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MTM1 overexpression prevents and reverts BIN1-related centronuclear myopathy.
    Giraud Q; Spiegelhalter C; Messaddeq N; Laporte J
    Brain; 2023 Oct; 146(10):4158-4173. PubMed ID: 37490306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological features of centronuclear myopathy in Japanese populations harboring mutations in dynamin 2.
    Mori-Yoshimura M; Okuma A; Oya Y; Fujimura-Kiyono C; Nakajima H; Matsuura K; Takemura A; Malicdan MC; Hayashi YK; Nonaka I; Murata M; Nishino I
    Clin Neurol Neurosurg; 2012 Jul; 114(6):678-83. PubMed ID: 22613877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mice with muscle-specific deletion of Bin1 recapitulate centronuclear myopathy and acute downregulation of dynamin 2 improves their phenotypes.
    Silva-Rojas R; Nattarayan V; Jaque-Fernandez F; Gomez-Oca R; Menuet A; Reiss D; Goret M; Messaddeq N; Lionello VM; Kretz C; Cowling BS; Jacquemond V; Laporte J
    Mol Ther; 2022 Feb; 30(2):868-880. PubMed ID: 34371181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single Intramuscular Injection of AAV-shRNA Reduces DNM2 and Prevents Myotubular Myopathy in Mice.
    Tasfaout H; Lionello VM; Kretz C; Koebel P; Messaddeq N; Bitz D; Laporte J; Cowling BS
    Mol Ther; 2018 Apr; 26(4):1082-1092. PubMed ID: 29506908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reducing dynamin 2 expression rescues X-linked centronuclear myopathy.
    Cowling BS; Chevremont T; Prokic I; Kretz C; Ferry A; Coirault C; Koutsopoulos O; Laugel V; Romero NB; Laporte J
    J Clin Invest; 2014 Mar; 124(3):1350-63. PubMed ID: 24569376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A centronuclear myopathy-dynamin 2 mutation impairs skeletal muscle structure and function in mice.
    Durieux AC; Vignaud A; Prudhon B; Viou MT; Beuvin M; Vassilopoulos S; Fraysse B; Ferry A; Lainé J; Romero NB; Guicheney P; Bitoun M
    Hum Mol Genet; 2010 Dec; 19(24):4820-36. PubMed ID: 20858595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcium homeostasis alterations in a mouse model of the Dynamin 2-related centronuclear myopathy.
    Fraysse B; Guicheney P; Bitoun M
    Biol Open; 2016 Nov; 5(11):1691-1696. PubMed ID: 27870637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotype variability and histopathological findings in centronuclear myopathy due to DNM2 mutations.
    Hanisch F; Müller T; Dietz A; Bitoun M; Kress W; Weis J; Stoltenburg G; Zierz S
    J Neurol; 2011 Jun; 258(6):1085-90. PubMed ID: 21221624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A rare case of centronuclear myopathy with
    Aghbolaghi AG; Lechpammer M
    Autops Case Rep; 2017; 7(2):43-48. PubMed ID: 28740838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNM2 mutations in a cohort of sporadic patients with centronuclear myopathy.
    Abath Neto O; Martins Cde A; Carvalho M; Chadi G; Seitz KW; Oliveira AS; Reed UC; Laporte J; Zanoteli E
    Genet Mol Biol; 2015 May; 38(2):147-51. PubMed ID: 26273216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNM2 mutations in Chinese Han patients with centronuclear myopathy.
    Lin P; Liu X; Zhao D; Dai T; Wu H; Gong Y; Yan C
    Neurol Sci; 2016 Jun; 37(6):995-8. PubMed ID: 26908122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A centronuclear myopathy-causing mutation in dynamin-2 disrupts neuronal morphology and excitatory synaptic transmission in a murine model of the disease.
    Arriagada-Diaz J; Flores-Muñoz C; Gómez-Soto B; Labraña-Allende M; Mattar-Araos M; Prado-Vega L; Hinostroza F; Gajardo I; Guerra-Fernández MJ; Bevilacqua JA; Cárdenas AM; Bitoun M; Ardiles AO; Gonzalez-Jamett AM
    Neuropathol Appl Neurobiol; 2023 Aug; 49(4):e12918. PubMed ID: 37317811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefits of therapy by dynamin-2-mutant-specific silencing are maintained with time in a mouse model of dominant centronuclear myopathy.
    Trochet D; Prudhon B; Mekzine L; Lemaitre M; Beuvin M; Julien L; Benkhelifa-Ziyyat S; Bui MT; Romero N; Bitoun M
    Mol Ther Nucleic Acids; 2022 Mar; 27():1179-1190. PubMed ID: 35282416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BIN1 modulation in vivo rescues dynamin-related myopathy.
    Lionello VM; Kretz C; Edelweiss E; Crucifix C; Gómez-Oca R; Messaddeq N; Buono S; Koebel P; Massana Muñoz X; Diedhiou N; Cowling BS; Bitoun M; Laporte J
    Proc Natl Acad Sci U S A; 2022 Mar; 119(9):. PubMed ID: 35217605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Muscle-specific function of the centronuclear myopathy and Charcot-Marie-Tooth neuropathy-associated dynamin 2 is required for proper lipid metabolism, mitochondria, muscle fibers, neuromuscular junctions and peripheral nerves.
    Tinelli E; Pereira JA; Suter U
    Hum Mol Genet; 2013 Nov; 22(21):4417-29. PubMed ID: 23813975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical, pathological, and genetic features of dynamin-2-related centronuclear myopathy in China.
    Chen T; Pu C; Wang Q; Liu J; Mao Y; Shi Q
    Neurol Sci; 2015 May; 36(5):735-41. PubMed ID: 25501959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiological impact and disease reversion for the severe form of centronuclear myopathy linked to dynamin.
    Massana Muñoz X; Kretz C; Silva-Rojas R; Ochala J; Menuet A; Romero NB; Cowling BS; Laporte J
    JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32809972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.